BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 14, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Apremilast: Phase III data

Top-line data from the double-blind, international Phase III ESTEEM 1 trial in 844 patients with moderate to severe plaque psoriasis showed that twice-daily 30 mg apremilast met the primary endpoint of improving PASI 75 response rate, defined as a >=75% improvement in PASI score from baseline, at week 16 vs. placebo. Apremilast also met the secondary endpoint of reducing sPGA scores from baseline...

Read the full 292 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >